2022
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases 2022, 76: 443-452. PMID: 36130191, PMCID: PMC9907485, DOI: 10.1093/cid/ciac783.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineReinfection riskArtemisinin-based combination therapyDay 7 levelsOverall drug exposureHigh transmission settingsYoung childrenAntimalarial exposureUncomplicated malariaExtended regimenRecurrent parasitemiaControlled TrialsPrimary outcomeCombination therapyKaplan-MeierDrug exposureTotal episodesUgandan childrenArtemisinin resistanceLumefantrine concentrationsPharmacodynamic studiesHigh riskPharmacokinetic parametersRecurrence riskDay 7
2016
Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children
Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S. Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infectious Diseases 2016, 3: ofw217. PMID: 28018925, PMCID: PMC5170492, DOI: 10.1093/ofid/ofw217.Peer-Reviewed Original ResearchParasite clearanceArtemether-lumefantrineDHA exposureUgandan childrenHuman immunodeficiency virus (HIV) infectionArtemether-lumefantrine treatmentDaily blood smearsEarly parasite clearanceInitial parasite clearanceImmunodeficiency virus infectionLopinavir/ritonavirHuman immunodeficiency virusParasite clearance ratesAL efficacyArtemisinin pharmacokineticsAntiretroviral therapyHIV statusImmunodeficiency virusPK exposureArtemisinin resistanceTreatment outcomesVirus infectionHIVPharmacokinetic parametersBlood smearsPopulation Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
Tchaparian E, Sambol NC, Arinaitwe E, McCormack SA, Bigira V, Wanzira H, Muhindo M, Creek DJ, Sukumar N, Blessborn D, Tappero JW, Kakuru A, Bergqvist Y, Aweeka FT, Parikh S. Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. The Journal Of Infectious Diseases 2016, 214: 1243-1251. PMID: 27471317, PMCID: PMC5034953, DOI: 10.1093/infdis/jiw338.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineRecurrent parasitemiaLumefantrine exposurePopulation pharmacokineticsUgandan childrenYoung Ugandan childrenPlasmodium falciparum malariaDay 7 concentrationsAge 6 monthsFirst-order absorptionWhole blood concentrationsYoung childrenUncomplicated malariaFalciparum malariaBlood concentrationsTreatment outcomesLumefantrine concentrationsSignificant positive correlationParasitemiaOlder childrenPharmacokineticsLumefantrineMalariaExposure levelsOpen model
2015
Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin‐Piperaquine for Uncomplicated Malaria
Sambol N, Yan L, Creek D, McCormack S, Arinaitwe E, Bigira V, Wanzira H, Kakuru A, Tappero J, Lindegardh N, Tarning J, Nosten F, Aweeka F, Parikh S. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin‐Piperaquine for Uncomplicated Malaria. Clinical Pharmacology & Therapeutics 2015, 98: 87-95. PMID: 25732044, PMCID: PMC5088713, DOI: 10.1002/cpt.104.Peer-Reviewed Original ResearchConceptsUncomplicated malariaPopulation pharmacokineticsYoung Ugandan childrenWeight-based dosingChildren 6 monthsAge-specific guidelinesClearance/bioavailabilityFirst-order absorptionDihydroartemisinin-PiperaquinePiperaquine exposureMalaria episodesProspective trialOral dosesUgandan childrenPlasma concentrationsThree-compartment modelDay 7High dosesAge groupsEarly childhoodPiperaquineDosingPharmacokineticsMalariaPhysiological changes
2009
Pharmacokinetics of Artemether-Lumefantrine and Artesunate-Amodiaquine in Children in Kampala, Uganda
Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark TD, Dorsey G, Lindegardh N, Annerberg A, Rosenthal PJ, Kamya MR, Aweeka F. Pharmacokinetics of Artemether-Lumefantrine and Artesunate-Amodiaquine in Children in Kampala, Uganda. Antimicrobial Agents And Chemotherapy 2009, 54: 52-59. PMID: 19841149, PMCID: PMC2798532, DOI: 10.1128/aac.00679-09.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyUncomplicated malariaActive metaboliteConcentration-time curveWorld Health OrganizationACT regimensArtesunate-AmodiaquineLast doseArtemether-lumefantrineLevel of exposureDrug regimensVenous samplingCombination therapyUgandan childrenPK parametersPharmacokinetic dataArtemisinin derivativesPK resultsOptimum dosingRegimensLumefantrineHealth OrganizationAdultsChildrenDesethylamodiaquine
2004
Host polymorphisms and the incidence of malaria in Ugandan children.
Parikh S, Dorsey G, Rosenthal PJ. Host polymorphisms and the incidence of malaria in Ugandan children. American Journal Of Tropical Medicine And Hygiene 2004, 71: 750-3. PMID: 15642965, DOI: 10.4269/ajtmh.2004.71.750.Peer-Reviewed Original ResearchConceptsInducible nitric oxide synthaseWild-type childrenUgandan childrenLower incidenceHost polymorphismsParasite densityNitric oxide synthaseLow parasite densitiesIncidence of malariaHigh parasite densitySymptomatic malariaUncomplicated malariaTumor necrosisIncidence rateOxide synthaseHigh incidencePromoter polymorphismGlucose-6-phosphate dehydrogenase AMale hemizygotesMalariaIncidencePreventative measuresGlucose-6-phosphate dehydrogenaseSickle hemoglobinDehydrogenase AMolecular Evaluation of the Natural History of Asymptomatic Parasitemia in Ugandan Children
Nsobya SL, Parikh S, Kironde F, Lubega G, Kamya MR, Rosenthal PJ, Dorsey G. Molecular Evaluation of the Natural History of Asymptomatic Parasitemia in Ugandan Children. The Journal Of Infectious Diseases 2004, 189: 2220-2226. PMID: 15181569, DOI: 10.1086/421281.Peer-Reviewed Original ResearchConceptsSymptomatic malariaPolymerase chain reactionAsymptomatic parasitemiaDetectable parasitemiaNatural historySubsequent clinical malariaClinical malariaAsymptomatic childrenSymptomatic episodesMalarial parasitemiaUgandan childrenPersistent infectionParasitemiaMalariaFirst monthChain reactionMolecular evaluationChildrenHigh ratePrevalenceSimilar ratesMonthsPersistent strainsEpisodesInfection